PMG
GSK icon

ProVise Management Group’s GSK GSK Stock Holding History

ProVise Management Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.68M Buy
120,951
+1,101
+0.9% +$59.7K 0.48% 60
2025
Q4 		$5.88M Buy
119,850
+462
+0.4% +$21.5K 0.42% 61
2025
Q3 		$5.15M Buy
119,388
+2,978
+3% +$116K 0.38% 60
2025
Q2 		$4.47M Buy
116,410
+1,659
+1% +$63.4K 0.35% 65
2025
Q1 		$4.45M Buy
114,751
+2,700
+2% +$98.8K 0.38% 66
2024
Q4 		$3.79M Sell
112,051
-11,304
-9% -$407K 0.32% 76
2024
Q3 		$5.04M Buy
123,355
+1,327
+1% +$54.3K 0.4% 68
2024
Q2 		$4.7M Sell
122,028
-1,575
-1% -$66.3K 0.4% 67
2024
Q1 		$5.3M Buy
123,603
+5,636
+5% +$232K 0.46% 67
2023
Q4 		$4.37M Buy
117,967
+45,874
+64% +$1.65M 0.37% 79
2023
Q3 		$2.61M Buy
+72,093
New +$2.56M 0.24% 101
2022
Q2 		– Sell
-6,425
Closed -$350K – 337
2022
Q1 		$350K Sell
6,425
-1,887
-23% -$102K 0.03% 263
2021
Q4 		$458K Sell
8,312
-1,960
-19% -$102K 0.04% 251
2021
Q3 		$491K Buy
10,272
+2,400
+30% +$121K 0.05% 229
2021
Q2 		$392K Hold
7,872
– – 0.04% 247
2021
Q1 		$351K Hold
7,872
– – 0.04% 255
2020
Q4 		$362K Buy
7,872
+14
+0.2% +$643 0.04% 237
2020
Q3 		$370K Hold
7,858
– – 0.05% 217
2020
Q2 		$401K Sell
7,858
-400
-5% -$20.5K 0.06% 196
2020
Q1 		$391K Sell
8,258
-211
-2% -$11.3K 0.07% 194
2019
Q4 		$497K Sell
8,469
-320
-4% -$17.8K 0.06% 199
2019
Q3 		$469K Sell
8,789
-649
-7% -$33.4K 0.06% 198
2019
Q2 		$472K Sell
9,438
-80
-0.8% -$4.01K 0.06% 209
2019
Q1 		$497K Sell
9,518
-1,950
-17% -$97.4K 0.07% 195
2018
Q4 		$548K Sell
11,468
-874
-7% -$43K 0.09% 184
2018
Q3 		$620K Buy
12,342
+80
+0.7% +$4.07K 0.08% 194
2018
Q2 		$618 Sell
12,262
-240
-2% -$12.1K 0.05% 199
2018
Q1 		$610K Buy
12,502
+1,280
+11% +$59.6K 0.09% 181
2017
Q4 		$497K Sell
11,222
-12,318
-52% -$569K 0.07% 207
2017
Q3 		$1.19M Sell
23,540
-400
-2% -$20.3K 0.17% 135
2017
Q2 		$1.29M Buy
23,940
+630
+3% +$33.6K 0.2% 129
2017
Q1 		$1.23M Sell
23,310
-728
-3% -$36.9K 0.2% 127
2016
Q4 		$1.16M Sell
24,038
-192
-0.8% -$9.48K 0.2% 130
2016
Q3 		$1.31M Buy
24,230
+1,296
+6% +$71.1K 0.23% 125
2016
Q2 		$1.24M Sell
22,934
-408
-2% -$21.5K 0.23% 118
2016
Q1 		$1.18M Buy
23,342
+3,350
+17% +$167K 0.24% 109
2015
Q4 		$1.01M Buy
+19,992
New +$1.02M 0.21% 126
2015
Q3 		– Sell
-23,537
Closed -$1.23M – 286
2015
Q2 		$1.23M Sell
23,537
-1,501
-6% -$84.5K 0.26% 106
2015
Q1 		$1.45M Sell
25,038
-412
-2% -$23.6K 0.31% 99
2014
Q4 		$1.36M Sell
25,450
-12,455
-33% -$697K 0.29% 103
2014
Q3 		$2.18M Sell
37,905
-3,220
-8% -$197K 0.47% 60
2014
Q2 		$2.75M Buy
41,125
+107
+0.3% +$7.24K 0.6% 43
2014
Q1 		$2.74M Buy
41,018
+2,499
+6% +$169K 0.66% 41
2013
Q4 		$2.57M Sell
38,519
-2,035
-5% -$132K 0.66% 38
2013
Q3 		$2.54M Buy
40,554
+25,007
+161% +$1.61M 0.72% 27
2013
Q2 		$971K Buy
+15,547
New +$987K 0.29% 98

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ProVise Management Group's GSK Position: Q1 2026 in Review

ProVise Management Group increased its GSK (GSK) stake by 0.92% in Q1 2026, buying an estimated $59.7K and bringing the position to 120,951 shares worth $6.68M. The position accounts for 0.48% of the portfolio, ranked #60.

ProVise Management Group first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • ProVise Management Group held 120,951 shares of GSK worth $6.68M as of Q1 2026.
  • ProVise Management Group bought 1,101 GSK shares in Q1 2026, an estimated $59.7K.
  • GSK made up 0.48% of ProVise Management Group's portfolio in Q1 2026, its #60 holding.
  • ProVise Management Group first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on ProVise Management Group's 13F filing for Q1 2026, filed 7 May 2026.